Prophylaxis against hepatitis B recurrence following liver transplantation in HBs Ag(+) patients

Hepatitis B Immunoglobulin and Lamivudine Improve Hepatitis B–Related Outcomes After Liver Transplantation: Meta-Analysis

“…Initially, 7 studies were identified from the total of 272 screened, but one was excluded because the outcome data could not be extracted for the 2 treatment groups (Figure 1). 16 Of the 6 eligible studies [17][18][19][20][21][22] included in the meta-analysis for HBV recurrence, 2 were prospective, 18,21 and 4 were retrospective 17,19,20,22 (Table 1). All studies were published in English and were conducted in the following countries: 1 each in Australia, 21 Spain, 22 and France, 18 and 3 in the United States.…”

Cost‐effective and safe ambulatory long‐term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation

“…Various protocols have been proposed – e.g. high‐dose therapy with 10 000 IU every 4 wk, or low‐dose therapy with 2000 IU every 2 wk; a promising combination of low‐dose HBIG and lamivudine also deserves attention (29–31). However, the average costs of i.v.…”

Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis

“…Of these, 931 clearly irrelevant publications were excluded. Of the 37 potentially eligible studies, 17 were excluded (20–36) (Fig. 1).…”